Medicines Co. (MDCO) Reports Q2 EPS of $2.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
The Medicines Company Reports Second-Quarter 2016 Business and Financial Results
July 27, 2016 7:01 AM EDTAdvanced potential blockbuster R&D programs
Completed divestiture of non-core cardiovascular assets
Refinanced substantial portion of near-term debt obligations
Transactions significantly strengthen balance sheet and provide valuable strategic and operational flexibility
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced its business and financial results for the second quarter ended June 30, 2016.
During the second quarter of 2016, the Company delivered strong execution against its strategic objectives by driving further advancement of its four potential blockbuster development... More
